Published in Dev Biol (Basel) on January 01, 2003
Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res (2011) 1.31
Role of analytical ultracentrifugation in assessing the aggregation of protein biopharmaceuticals. AAPS J (2006) 1.26
Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses. J Biol Chem (2012) 1.09
Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice. J Pharm Sci (2006) 1.04
Issues related to targeted delivery of proteins and peptides. AAPS J (2006) 0.98
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. J Neurol (2007) 0.89
Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII. AAPS J (2009) 0.84
Self-aggregation of a recombinant form of the propeptide NH2-terminal of the precursor of pulmonary surfactant protein SP-B: a conformational study. J Ind Microbiol Biotechnol (2008) 0.79
Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1988) 5.99
The hepatitis delta (delta) virus possesses a circular RNA. Nature (1986) 4.00
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science (1986) 3.33
Cloned HBV DNA causes hepatitis in chimpanzees. Nature (1982) 2.80
The purification and characterization of rat gamma interferon by use of two monoclonal antibodies. J Gen Virol (1986) 2.29
Infectious hepatitis B virus from cloned DNA of known nucleotide sequence. Proc Natl Acad Sci U S A (1985) 2.20
Transmission of hepatitis B from hepatitis-B-seronegative subjects. Lancet (1988) 1.95
Sequence evolution of the hypervariable region in the putative envelope region E2/NS1 of hepatitis C virus is correlated with specific humoral immune responses. J Virol (1995) 1.63
Monoclonal antibodies to human immune interferon and their use in a sensitive solid-phase ELISA. J Immunol Methods (1985) 1.62
Hepatitis B virus antigens made in microbial cells immunise against viral infection. EMBO J (1984) 1.54
Gamma-interferon treatment inhibits collagen deposition in murine schistosomiasis. Hepatology (1989) 1.47
Cloning and expression of the chromosomal immune interferon gene of the rat. EMBO J (1985) 1.47
[Pulmonary infection with Coccidioides immitis]. Ned Tijdschr Geneeskd (1996) 1.39
Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci U S A (1990) 1.39
[Neurological complications of infectious mononucleosis in 3 patients]. Ned Tijdschr Geneeskd (1994) 1.37
The cost-effectiveness of drug regulation: the example of thorough QT/QTc studies. Clin Pharmacol Ther (2011) 1.32
Cytokines and the immune response. Biotherapy (1996) 1.15
Isolation and characterization of monoclonal antibodies directed to rat interferon-gamma. Lymphokine Res (1989) 1.13
Taking immunogenicity assessment of therapeutic proteins to the next level. Biologicals (2011) 1.12
Induction of natural killer cell activity and allocytotoxicity in human peripheral blood lymphocytes after mixed lymphocyte culture. Scand J Immunol (1981) 1.10
Glomerular mesangial cells in local inflammation. Induction of the expression of MHC class II antigens by IFN-gamma. J Immunol (1989) 1.09
[Introduction of immunotherapeutic agents in clinical practice; current status concerning anti-endotoxin antibody HA-1A in the control of sepsis]. Ned Tijdschr Geneeskd (1993) 1.06
Protective immunisation against hepatitis B with an internal antigen of the virus. J Med Virol (1987) 1.05
Double-blind study of leucocyte interferon administration in chronic HBsAg-positive hepatitis. Lancet (1980) 1.02
Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe. Clin Pharmacol Ther (2010) 1.01
Cloning, expression, and purification of rat IFN-gamma. Methods Enzymol (1986) 1.00
Antiviral effect of interferon in vivo may be mediated by the host. Nature (1979) 1.00
Mechanism of escape of exoerythrocytic forms (EEF) of malaria parasites from the inhibitory effects of interferon-gamma. J Immunol (1987) 0.99
Identification and transmission of hepatitis B virus-related variants. Proc Natl Acad Sci U S A (1986) 0.99
Production and initial characterization of rat interferon. J Gen Virol (1980) 0.98
Tumour necrosis factor-alpha, interferon-gamma and interferon-beta exert antiviral activity in nervous tissue cells. J Gen Virol (1991) 0.97
Reduced synthesis of pp60src and expression of the transformation-related phenotype in interferon-treated Rous sarcoma virus-transformed rat cells. Mol Cell Biol (1983) 0.96
Iatrogenic meningitis by Streptococcus salivarius following lumbar puncture. J Hosp Infect (1995) 0.96
Simple method for measuring growth inhibition by interferon of cells in monolayer. J Virol Methods (1980) 0.94
Influence of interferon preparations on the proliferative capacity of human and mouse bone marrow cells in vitro. Cancer Res (1978) 0.93
Impact of class II major histocompatibility complex antigen expression on the immunogenic potential of isolated rat vascular endothelial cells. Transplantation (1987) 0.92
Plasmodium falciparum: studies on mature exoerythrocytic forms in the liver of the chimpanzee, Pan troglodytes. Exp Parasitol (1990) 0.91
Structure and expression in Escherichia coli of a cloned rat interferon-alpha gene. Nucleic Acids Res (1984) 0.91
Longitudinal analysis of hepatitis C virus infection and genetic drift of the hypervariable region. J Infect Dis (1994) 0.91
Suppression and augmentation of rat adjuvant arthritis with monoclonal anti-interferon-gamma antibody. Clin Exp Immunol (1989) 0.90
Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy (1997) 0.87
Antagonistic effects of gamma interferon and steroids on tissue antigenicity. J Exp Med (1986) 0.86
Effect of treatment with interferon and cyclophosphamide on the growth of a spontaneous liposarcoma in rats. Int J Cancer (1983) 0.86
A sensitive two-site enzyme immunoassay for the detection of rat interferon-gamma in biological fluids. J Interferon Res (1990) 0.86
Fibroblast interferon in HBsAg-positive chronic active hepatitis. Lancet (1977) 0.85
The value of non-human primates in the development of monoclonal antibodies. Nat Biotechnol (2013) 0.85
Chemical inactivation of hepatitis B virus: the effect of disinfectants on virus-associated DNA polymerase activity, morphology and infectivity. J Virol Methods (1983) 0.85
Rat cytomegalovirus: induction of and sensitivity to interferon. Antiviral Res (1983) 0.85
Comparative antiviral efficiency of leukocyte and bacterially produced human alpha-interferon in rhesus monkeys. Nature (1981) 0.84
Antiviral activity of recombinant rat interferon gamma in immunologically impaired and immunosuppressed rats. J Gen Virol (1988) 0.84
Hepatitis delta virus cDNA sequence from an acutely HBV-infected chimpanzee: sequence conservation in experimental animals. J Med Virol (1991) 0.84
Significance of neutralizing antibodies to interferon beta during treatment of multiple sclerosis: expert opinions based on the Proceedings of an International Consensus Conference. Eur J Neurol (2005) 0.83
Hepatitis B after infection of a chimpanzee with cloned HBV DNA. Dev Biol Stand (1983) 0.82
The cost-effectiveness of periodic safety update reports for biologicals in Europe. Clin Pharmacol Ther (2013) 0.82
Prevention of vaccinia lesions in Rhesus monkeys by human leucocyte and fibroblast interferon. J Gen Virol (1980) 0.82
Double-blind study of interferon administration in renal transplant recipients. Eur J Clin Invest (1978) 0.81
Differential effects of fibroblast and leucocyte interferon in HBsAg positive chronic active hepatitis. Eur J Clin Invest (1979) 0.81
Antiviral and side effects of interferons produced by recombinant DNA techniques as tested in rhesus monkeys. Antiviral Res (1982) 0.81
Differential sensitivity of Rauscher murine leukaemia virus (MuLV-R) to interferons in two interferon-responsive cell lines. J Gen Virol (1976) 0.81
Influence of input multiplicity of infection on the antiviral activity of interferon. J Gen Virol (1980) 0.81
A phase I clinical tolerance study of rDNA alpha 2 human interferon in patients with non-reticuloendothelial system malignancies. Eur J Cancer Clin Oncol (1983) 0.80
A framework for improving the quality of care for people with psoriasis. J Eur Acad Dermatol Venereol (2012) 0.80
Effect of recombinant interferon gamma and interleukin-2 and of a monoclonal antibody against interferon gamma on the rat immune response against heart allografts. J Heart Lung Transplant (1991) 0.80
Phytohaemagglutinin-induced susceptibility to lysis by natural and activated killer cells of autologous allogeneic and xenogeneic target cells. Mol Immunol (1982) 0.79
Serum capacity to inhibit reverse transcriptase in vitro distinguishes HIV-1 infection from HIV-2 or SIV infection. AIDS Res Hum Retroviruses (1989) 0.79
Antiviral activity of interferon in rats and the effect of immune suppression. J Gen Virol (1984) 0.79
Neonatal host defense mechanisms against Listeria monocytogenes infection: the role of lipopolysaccharides and interferons. Pediatr Res (1989) 0.79
Cloning, expression, and purification of rat IFN-alpha 1. Methods Enzymol (1986) 0.79
Pharmacokinetic studies with human and rat interferons-gamma in different species. J Interferon Res (1986) 0.79
Occupational associations among British Columbia male cancer patients. Can J Public Health (1990) 0.78
Leukocyte binding and Ia-expression in vascular endothelium. Transplant Proc (1987) 0.78
The chimpanzee as a model to test the side effects of human interferons. J Med Primatol (1984) 0.77
Biological effect of interferon-gamma during the course of experimental infection of rat by Schistosoma mansoni. Cell Immunol (1990) 0.77
Vascular endothelium in allograft rejection. Transplant Proc (1988) 0.77
Production, purification, and characterization of rat interferon from transformed rat cells. Methods Enzymol (1986) 0.77
Appropriate conditions for maintenance of chimpanzees in studies with blood-borne viruses: an epidemiologic and psychosocial perspective. J Med Primatol (1989) 0.77
In vivo antiproliferative effects of gamma-interferon and tumor necrosis factor alpha in a rat renal cell carcinoma model system. J Urol (1990) 0.76
Hepatitis C virus antibody detection by a line immunoassay and (near) full length genomic RNA detection by a new RNA-capture polymerase chain reaction. J Med Virol (1992) 0.76
Biological and molecular characterization of the hepatitis delta virus. Prog Clin Biol Res (1987) 0.76
The sponsored pandemic of the Mexican flu? Int J Risk Saf Med (2011) 0.76
Circulating interferon in rabbits and monkeys after administration of human gamma interferon by different routes. J Gen Virol (1983) 0.76
Neonatal Listeria monocytogenes infection is refractory to interferon. Pediatr Res (1991) 0.76
Protective efficacy of a novel hepatitis B vaccine consisting of M (pre-S2 + S) protein particles (a third generation vaccine). Vaccine (1990) 0.76
Spending on BSE research. Nature (1996) 0.75
Health risks of genetically modified foods. Lancet (1999) 0.75
[Selective serotonin reuptake inhibitors (SSRI's) are not indicated for children and adolescents with depression]. Ned Tijdschr Geneeskd (2005) 0.75
Prophylactic use of interferon in renal allograft recipients. Transplant Proc (1979) 0.75
Isolation of parainfluenza virus type 3 from cerebrospinal fluid. J Infect Dis (1992) 0.75
Chimpanzees and AIDS research. Nature (1988) 0.75
Recombinant interferon-gamma applied to the brain ventricular system protects rats against pseudorabies. J Neuroimmunol (1990) 0.75
Protection of rats against pseudorabies virus infection by gamma-interferon. Proc Soc Exp Biol Med (1989) 0.75
The risk-based approach to ATMP development - generally accepted by regulators but infrequently used by companies. Regul Toxicol Pharmacol (2013) 0.75
Between clones and clinic. Biotherapy (1988) 0.75
Modulation of the immune response by interferon gamma administration in a rat cardiac allograft model. Transplant Proc (1989) 0.75
Growth inhibition and eicosanoid metabolism in the R3230AC mammary adenocarcinoma by interferon. Cancer Treat Rep (1986) 0.75
Concomitant enhancement of a cytoskeleton-associated 76,000-dalton protein and inhibition of fluid-phase pinocytosis by interferon-alpha in Fujinami sarcoma virus-transformed rat 3Y1 cells. J Interferon Res (1986) 0.75
The effects of recombinant and natural human interferons in vaccinia virus infected rhesus monkeys. Antiviral Res (1985) 0.75
Human interferon does not protect cowpea plant cell protoplasts against infection with alfalfa mosaic virus. Virology (1985) 0.75